This application requests support of the administration and data management necessary for the Cancer Center of the University of South Alabama to perform clinical investigative studies as a member of the Southwest Oncology Group (SWOG), to permit development of cancer control programs for this geographic area and to provide the support necessary to develop CGOP's in this region. The University of South Alabama Hospital is the major teaching hospital of this institution. It is the only university hospital within a 150 mile radius on the Gulf Coast and serves southern Alabama, southern Mississippi and the panhandle of Florida. It is the only hospital in this region willing and capable of providing oncologic care for patients regardless of payment capability. The population throughout this geographic area varies from 15 to 70 percent Black. There are areas with large populations of American Indians and several Indian reservations. Further, the climate and fishing industry has attracted significant numbers of immigrants from Vietnam and Cambodia to this area. This assures a continuing hospital census with the majority of patients being from minority populations. Presently, there is an established relationship with both SWOG and the Pediatric Oncology Group (POG). Prospective arrangements have been made for collaboration with the MD Anderson Cancer Center (MSKCC). The University of South Alabama Hospital has 410 beds and 30 beds are on a designated adult oncology unit. Approximately 550 new cancer patients are seen yearly at this facility and subsequently followed in the Cancer Center following discharge. The University affiliated with the Southeastern Oncology Group (SEG) in 1983 following completion of the Cancer Center building. Following dissolution of the SEG in 1986, it joined SWOG. SWOG is unable to provide funding of our administrative and data management needs until the next funding cycle in late 1992 because they were not budgeted for it in their current grant. Review of records of cancer patients placed on either SEG or SWOG protocols between 1983 and present show 56 percent were from minority populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA052654-04
Application #
2094887
Study Section
Special Emphasis Panel (SRC (86))
Project Start
1990-09-14
Project End
1998-05-31
Budget Start
1994-08-08
Budget End
1995-05-31
Support Year
4
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of South Alabama
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Mobile
State
AL
Country
United States
Zip Code
36688
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Malhotra, Binu; Moon, James; Kucuk, Omar et al. (2014) Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329. Head Neck 36:1712-7
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70

Showing the most recent 10 out of 97 publications